IDEAYA Biosciences teams with Genentech to test IDE892 with KRAS G12D drug in pancreatic cancer
Reuters2026/08/19 10:01- IDEAYA Biosciences entered a clinical collaboration with Genentech to test IDE892 with KRAS G12D inhibitor GDC-7035 (RG6620) in PDAC.
- Trial targets patients with MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma; Genentech will sponsor the study under joint governance.
- IDEAYA will supply IDE892; each party keeps commercial rights to its compound for monotherapy or combination use.
- Companies estimate MTAP deletions and KRAS G12D mutations co-occur in up to about 15% of PDAC patients.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan: Tesla (TSLA.US) Robotaxi revenue may reach $320 billions by 2035, with nearly 98% coming from its own fleet
JPMorgan analyst Rajat Gupta released a research report last week, estimating that by 2035, Tesla's Robotaxi revenue will reach approximately $320 billion, with nearly $314 billion coming from Tesla's own and operated fleet, rather than from the owner-operated "Tesla Network."
FDA approves Telix brain cancer imaging drug Pixclara for glioma PET scans
Charles Hoskinson Says AI Has Destroyed The Old Crypto Growth Metric
Kvika appoints Jón Birgir Jónsson as CEO, effective Dec. 1
Crypto prices
More
